Skip to Content

'
Roy S. Herbst, M.D., Ph.D.

Present Title & Affiliation

Primary Appointment

Professor of Medicine, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Chief, Section of Thoracic Medical Oncology, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Barnhart Family Distinguished Professor in Targeted Therapies, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Office Address

The University of Texas M. D. Anderson Cancer Center
1515 Holcombe Boulevard
Unit Number: 432
Houston, TX 77030
Room Number: FC9.3020
Phone: (713) 792-6363
Fax: (713) 792-1220

Education & Training

Degree-Granting Education

1997 Harvard University, Cambridge, MA, MS, Clinical Translational Research
1991 Cornell University Medical College, New York, NY, MD, Medicine
1990 The Rockefeller University, New York, NY, PHD, Molecular Cell Biology (Thesis Advisors: James E. Darnell, Jr., M.D., and Lee E. Babiss, Ph.D.)
1984 Yale University, New Haven, CT, BS, Molecular Biophysics and Biochemistry
1984 Yale University, New Haven, CT, MS, Molecular Biophysics and Biochemistry

Postgraduate Training

1996-1997 Medical Hematology Fellowship, Brigham and Women's Hospital, Boston, MA, (Director: Dr. Robert Handin)
1995-1997 Clinical Investigator Training Program, MIT-Harvard (HST Program), Cambridge, MA, (Directors: Dr. Donald Kufe and Dr. Robert Rubin)
1994-1996 Medical Oncology Fellowship, Dana Farber Cancer Institute, Boston, MA, (Residency Director: Dr. Robert Mayer)
1994 Chief Medical Residency, West Roxbury VA Hospital, Dedham, MA, (Residency Director: Dr. George Thibault)
1991-1994 Clinical Fellowship in Medicine (Internship and Residency), Harvard Medical School, Boston, MA, (Residency Director: Dr. Marshall Wolf)

Selected Publications

Peer-Reviewed Original Research Articles
1. Salmon S, Chen H, Chen S, Herbst R, Tsao A, Tran H, Sandler A, Billheimer D, Shyr Y, Lee JW, Massion P, Brahmer J, Schiller J, Carbone D, Dang TP. Classification by Mass Spectrometry Can Accurately and Reliably Predict Outcome in Patients with Non-small Cell Lung Cancer Treated with Erlotinib-Containing Regimen. J Thorac Oncol 4(6):689-96, 6/2009. PMID: 19404214.
2. Hanrahan EO, Ryan AJ, Mann H, Kennedy SJ, Langmuir P, Natale RB, Herbst RS, Johnson BE, Heymach JV. Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res 15(10):3600-9, 5/2009. e-Pub 5/2009. PMID: 19447868.
3. Herbst RS, Hirsch FR. Patient selection criteria and the FLEX Study. Lancet 373(9674):1497-8, 5/2009. PMID: 19410696.
4. Kim ES, Mauer AM, William WN, Tran HT, Liu D, Lee JJ, Windt P, Hong WK, Vokes EE, Herbst RS. A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer. Cancer 115(8):1713-22, 4/2009. PMID: 19208430.
5. Craft BS, Kurzrock R, Lei X, Herbst R, Lippman S, Fu S, Karp DD. The changing face of Phase 1 cancer clinical trials: new challenges in study requirements. Cancer 115(8):1592-7, 4/2009. PMCID: PMC2668727.
6. Giaccone G, Iacona RB, Fandi A, Janas M, Ochs JS, Herbst RS, Johnson DH. Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy. J Cancer Res Clin Oncol 135(3):467-76, 3/2009. e-Pub 9/2008. PMID: 18787840.
7. Herbst RS, Lynch TJ, Sandler AB. Beyond doublet chemotherapy for advanced non-small-cell lung cancer: combination of targeted agents with first-line chemotherapy. Clin Lung Cancer 10(1):20-7, 1/2009. PMID: 19289368.
8. Zinner RG, Komaki R, Cox JD, Glisson BS, Pisters KM, Herbst RS, Kies M, Liao Z, Hong WK, Fossella FV. Dose Escalation of Gemcitabine Is Possible with Concurrent Chest Three-Dimensional Rather than Two-Dimensional Radiotherapy: A Phase I Trial in Patients with Stage III Non-Small-Cell Lung Cancer. Int J Radiat Oncol Biol Phys 73(1):119-27, 1/2009. e-Pub 6/2008. PMID: 18556142.
9. Rice D, Swisher S, Pisters K, Fossella F, Herbst R, Hofstetter W, Kies M, Komaki R, Lippman S, Mehran R, Roth J, Stewart D, Vaporciyan A, Walsh G, Cox J. Comment on "Treatment of non-small cell lung cancer stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition)". Chest 134(6):1349; author reply 1350, 12/2008. PMID: 19059972.
10. Herbst RS, Sandler A. Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC. Oncologist 13(11):1166-76, 11/2008. PMID: 18997180.
11. Heymach JV, Paz-Ares L, De Braud F, Sebastian M, Stewart DJ, Eberhardt WE, Ranade AA, Cohen G, Trigo JM, Sandler AB, Bonomi PD, Herbst RS, Krebs AD, Vasselli J, Johnson BE. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 26(33):5407-15, 11/2008. PMID: 18936474.
12. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 359(13):1367-80, 9/2008. PMID: 18815398.
13. Hirsch FR, Herbst RS, Olsen C, Chansky K, Crowley J, Kelly K, Franklin WA, Bunn PA, Varella-Garcia M, Gandara DR. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 26(20):3351-7, 7/2008. PMID: 18612151.
14. Vermorken JB, Herbst RS, Leon X, Amellal N, Baselga J. Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies. Cancer 112(12):2710-9, 6/2008. PMID: 18481809.
15. Ashkenazi A, Herbst RS. To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest 118(6):1979-90, 6/2008. PMCID: PMC2396896.
16. Einhorn LH, Bonomi P, Bunn PA, Camidge DR, Carbone DP, Choy H, Dubinett SM, Gandara DR, Gaspar LE, Govindan R, Johnson DH, Minna JD, Scagliotti G, West HJ, Herbst RS. Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer. J Thorac Oncol 3(5):545-55, 5/2008. PMID: 18449013.
17. Mullani NA, Herbst RS, O'Neil RG, Gould KL, Barron BJ, Abbruzzese JL. Tumor Blood Flow Measured by PET Dynamic Imaging of First-Pass 18F-FDG Uptake: A Comparison with 15O-Labeled Water-Measured Blood Flow. J Nucl Med 49(4):517-23, 4/2008. e-Pub 3/2008. PMID: 18344436.
18. Marom EM, Martinez CH, Truong MT, Lei X, Sabloff BS, Munden RF, Gladish GW, Herbst RS, Morice RC, Stewart DJ, Jimenez CA, Blumenschein GR, Onn A. Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer. J Thorac Oncol 3(4):351-7, 4/2008. PMID: 18379352.
19. Herbst RS. Bevacizumab/chemotherapy in non-small-cell lung cancer: looking for a few good men? Clin Lung Cancer 9(2):75-6, 3/2008. PMID: 18501092.
20. Oh Y, Herbst RS, Burris H, Cleverly A, Musib L, Lahn M, Bepler G. Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer. J Clin Oncol 26(7):1135-41, 3/2008. PMID: 18309949.
21. Miller VA, Riely GJ, Zakowski MF, Li AR, Patel JD, Heelan R, Kris MG, Sandler AB, Carbone DP, Tsao A, Herbst RS, Heller G, Ladanyi M, Pao W, Johnson DH. Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma BAC Subtype Predict Response to Erlotinib. J Clin Oncol 26(9):1472-8, 3/2008.
22. Miller VA, Riely GJ, Zakowski MF, Li AR, Patel JD, Heelan RT, Kris MG, Sandler AB, Carbone DP, Tsao A, Herbst RS, Heller G, Ladanyi M, Pao W, Johnson DH. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 26(9):1472-8, 3/2008. PMID: 18349398.
23. Xian Zhou, Suyu Liu, Kim ES, Herbst RS, Lee JJ. Bayesian adaptive design for targeted therapy development in lung cancer -- a step toward personalized medicine. Clin Trials 5(3):181-93, 2008. PMID: 18559407.
24. Heymach JV, Johnson BE, Prager D, Csada E, Roubec J, Pesek M, Spásová I, Belani CP, Bodrogi I, Gadgeel S, Kennedy SJ, Hou J, Herbst RS. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 26(1)(27):165-6, 2008. PMID: 17878479.
25. Shibuya K, Komaki R, Shintani T, Itasaka S, Ryan A, Jürgensmeier JM, Milas L, Ang K, Herbst RS, O'Reilly MS. Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 69(5):1534-43, 12/2007. PMCID: PMC2151850.
26. Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, Melnyk O, Ramies D, Lin M, Sandler A. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 25(30). e-Pub 10/1/2007. PMID: 17909199.
27. Herbst RS, Davies AM, Natale RB, Dang TP, Schiller JH, Garland LL, Miller VA, Mendelson D, Van den Abbeele AD, Melenevsky Y, de Vries DJ, Eberhard DA, Lyons B, Lutzker SG, Johnson BE. Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Clin Cancer Res 13(20):6175-81, 10/2007. PMID: 17947484.
28. Wu W, O'Reilly MS, Langley RR, Tsan RZ, Baker CH, Bekele N, Tang XM, Onn A, Fidler IJ, Herbst RS. Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice. Mol Cancer Ther 6(10):2652-63, 10/2007. PMID: 17913856.
29. Herbst RS, Oh Y, Wagle A, Lahn M. Enzastaurin, a protein kinase Cbeta- selective inhibitor, and its potential application as an anticancer agent in lung cancer. Clin Cancer Res 13(15 Pt 2)(15 Pt 2):s4641-6, 8/2007. PMID: 17671157.
30. Lynch TJ, Bonomi PD, Butts C, Davies AM, Engelman J, Govindan R, Herbst RS, Heymach JV, Johnson BE, Martins RG, Perez-Soler R, Riely GJ, Sandler AB, Sequist LV, Socinski MA, Wong KK, Hart CS. Novel agents in the treatment of lung cancer: Fourth Cambridge Conference. Clin Cancer Res (15 Pt 2)(15 Pt 2):s4583-8, 8/2007. PMID: 17671145.
31. Huang EH, Liao Z, Cox JD, Guerrero TM, Chang JY, Jeter M, Borghero Y, Wei X, Fossella F, Herbst RS, Blumenschein GR Jr, Moran C, Allen PK, Komaki R. Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone. Int J Radiat Oncol Biol Phys 68(3)(3):779-85, 7/2007. e-Pub 4/2007. PMID: 17418967.
32. Cohen MZ, Slomka J, Pentz RD, Flamm AL, Gold D, Herbst RS, Abbruzzese JL. Phase I participants' views of quality of life and trial participation burdens. Support Care Cancer 15(7)(7):885-890, 7/2007. e-Pub 1/2007. PMID: 17252219.
33. Rosen LS, Kurzrock R, Mulay M, Van Vugt A, Purdom M, Ng C, Silverman J, Koutsoukos A, Sun YN, Bass MB, Xu RY, Polverino A, Wiezorek JS, Chang DD, Benjamin R, Herbst RS. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 25(17):2369-76, 6/10/2007. PMID: 17557949.
34. Rosen L, Kurzrock R, Mulay M, Van Vugt a, Boughton DK, Purdom MA, ng C, Koutsoukos A, Sun Y-N, Bass MB, Polverino A, Wiezorek JS, Chang DD, Benjamin R, Herbst RS. Safety, pharmacokinetics, and efficacy of AMG 706, an investigational, oral, multi-kinase inhibitor in patients with advanced solid tumors. J Clin Oncol 25(17):2369-76, 6/2007.
35. Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD, Bekele BN, Herbst RS, Wistuba II. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 13(10)(10):2890-6, 5/2007. PMID: 17504988.
36. Ozols RF, Herbst RS, Colson YL, Gralow J, Bonner J, Curran WJ Jr, Eisenberg BL, Ganz PA, Kramer BS, Kris MG, Markman M, Mayer RJ, Raghavan D, Reaman GH, Sawaya R, Schilsky RL, Schuchter LM, Sweetenham JW, Vahdat LT, Winn RJ; American Society of Clinical Oncology. Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol 25(1)(1):146-162, 2007. e-Pub 12/8/2006. PMID: 17158528.
37. Herbst RS, Davies AM, Natale RB, Dang TP, Schiller JH, Garland LL, Miller VA, Mendselson D, Van den Abbeele AD, Melenevsky Y, de Vries, DJ, Ederhard, DA, Lyons B, Lutzker SG, Johnson BE. Efficacy and safety of single agent Pertuzxumab, a HER Dimerization Inhibitor, in Patients with Non-Small-Cell Lung Cancer. Clin Cancer Res 13(20):6175-6181, 2007.
38. Itaska S, Komaki R, Herbst RS, Shibuya K, Shintani T, Hunter NR, Onn A, Bucana CD, Milas L, Ang KK, O'rielly MS. Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice. Int J Radiat Oncol Biol Phys 67(3)(3):870-8, 2007. PMCID: PMC1976280.
39. Herbst RS, O'Neill VJ, Fehrenbacher L, Belani C, Bonomi PD, Hart LL, Melnyk O, Ramies D, Lin M, Sandler AB. Phase II study of efficacy and safety of bevacizumab (avastin) in combination with chemotherapy or erlotinib (tarceva) compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 25(30):4743-4750, 2007.
40. Wu W, Onn A, Isobe T, Itasaka S, Langley RR, Shitani T, Shibuya K, Komaki R, Ryan AJ, Fidler IJ, Herbst RS, O'Reilly MS. Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol Cancer Ther 6(2)(2):471-83, 2007. PMID: 17308046.
41. Pentz RD, Flamm AL, Sugarman J, Cohen MZ, Xu Z, Herbst RS, Abbruzzese JL. Who should go first in trials with scarce agents? The views of potential participants. IRB (4)(4):1-6, Jul-Aug, 2007. PMID: 17847620.
42. Herbst RS. Toxicities of antiangiogenic therapy in non-small-cell lung cancer. Clin Lung Cancer 8 Suppl 1:S23-30, 12/2006. PMID: 17239287.
43. Oh SH, Lee OH, Schroeder CP, Oh YW, Ke S, Cha HJ, Park RW, Onn A, Herbst RS, Li C, Lee HY. Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor-independent urokinase-type plasminogen activator inhibition. Mol Cancer Ther 5(11):2685-95, 11/2006. PMID: 17121915.
44. Herbst RS. Therapeutic options to target angiogenesis in human malignancies. Expert Opin Emerg Drugs 11(4):635-50, 11/2006. PMID: 17064223.
45. Govindan R, Natale R, Wade J, Herbst R, Krebs A, Reiling R, Hensing T, Wozniak A, Belani CP, Kelly K, Ochs J. Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program. Lung Cancer 53(3):331-7, 9/2006. e-Pub 6/23/2006. PMID: 16797779.
46. Carducci MA, Musib L, Kies MS, Pili R, Truong M, Brahmer JR, Cole P, Sullivan R, Riddle J, Schmidt J, Enas N, Sinha V, Thornton DE, Herbst RS. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol 24(25):4092-9, 9/2006. PMID: 16943527.
47. Heymach JV, Nilsson M, Blumenschein G, Papadimitrakopoulou V, Herbst R. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin Cancer Res 12(14 Pt 2):4441s-4445s, 7/2006. PMID: 16857825.
48. Thomas SK, Fossella FV, Liu D, Schaerer R, Tsao AS, Kies MS, Pisters KM, Blumenschein GR, Jr, Glisson BS, Lee JJ, Herbst RS, Zinner RG. Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. Clin Lung Cancer 7(5):326-31, 3/2006. PMID: 16640804.
49. Herbst RS, Bajorin DF, Bleiberg H, Blum D, Hao D, Johnson BE, Ozols RF, Demetri GD, Ganz PA, Kris MG, Levin B, Markman M, Raghavan D, Reaman GH, Sawaya R, Schuchter LM, Sweetenham JW, Vahdat LT, Vokes EE, Winn RJ, Mayer RJ. Clinical cancer advances 2005: Major research advances in cancer treatment, prevention, and screening--A report from the American Society of Clinical Oncology. J Clin Oncol 24(1):190-205, 1/2006. PMID: 16326753.
50. Vokes E, Herbst RS, Sandler A. Angiogenesis inhibition in the treatment of lung cancer. Clin Adv Hematol Oncol 4(11 Suppl 23):1-12, 2006. PMID: 17143257.
51. Sandler A, Herbst RS. Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways. Clin Cancer Res 12(14)(14 Pt 2):4421s-4425s, 2006. PMID: 16857821.
52. Green LJ, Marder P, Ray C, Cook CA, Jaken S, Musib LC, Herbst RS, Carducci M, Britten CD, Basche M, Eckhardt SG, Thornton D. Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor. Clin Cancer Res 12(11 Pt 1):3408-3415, 2006. PMID: 16740765.
53. Govindan R, Natale R, Wade J, Herbst RS. Efficacy and safety of gefitinib in chemonaive patients with advanced non small cell lung cancer treated in and expanded access program. Lung Cancer 53(3):331-337, 2006.
54. Carducci MA, Musib L, Kies MS, Pili R, Truong M, Brahmer JR, Cole P, Sullivan R, Riddle J, Schmidt J, Enas N, Sinha V, Thorton, DE, Herbst RS. Enzastaruin (LY317615), an oral PKCbeta (PKCβ) inhibitor, in patients with advanced cancer: a phase I dose escalation and pharmacokinetic study. J Clnic Oncol 24(25):4092-4099, 2006.
55. Fujimoto N, Wislez M, Zhang J, Iwanaga K, Dackor J, Hanna AE, Kalyankrishna S, Cody DD, Price RE, Sato M, Shay JW, Minna JD, Peyton M, Tang X, Massarelli E, Herbst R, Threadgill DW, Wistuba II, Kurie JM. High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. Cancer Res 65(24):11478-85, 12/2005. PMID: 16357156.
56. Robert F, Blumenschein G, Herbst RS, Fossella FV, Tseng J, Saleh MN, Needle M. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol 23(36):9089-96, 12/2005. PMID: 16301597.
57. Zinner RG, Fossella FV, Gladish GW, Glisson BS, Blumenschein GR, Papadimitrakopoulou VA, Pisters KM, Kim ES, Oh YW, Peeples BO, Ye Z, Curiel RE, Obasaju CK, Hong WK, Herbst RS. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer 104(11):2449-56, 12/2005. PMID: 16258975.
58. Gandara DR, Vallieres E, Gaspar LE, Kelly K, Albain KS, Herbst RS, Lara PN Jr, Mack P, Gumerlock PH, Crowley JJ. Therapeutic strategies for combined-modality therapy of locally advanced-stage non-small-cell lung cancer: rationale for consolidation docetaxel therapy. Clin Lung Cancer 3:S93-7, 12/2005. PMID: 16384543.
59. Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenschneider MJ, Iacona RB, Krebs AD, Johnson DH, Giaccone G, Herbst RS, Manegold C, Fukuoka M, Kris MG, Baselga J, Ochs JS, Haber DA. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 23(31):8081-92, 11/2005. PMID: 16204011.
60. Onn A, Choe DH, Herbst RS, Correa AM, Munden RF, Truong MT, Vaporciyan AA, Isobe T, Gilcrease MZ, Marom EM. Tumor cavitation in stage I non-small cell lung cancer: epidermal growth factor receptor expression and prediction of poor outcome. Radiology 237(1):342-7, 10/2005. PMID: 16183941.
61. Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Janne PA, Januario T, Johnson DH, Klein P, Miller VA, Ostland MA, Ramies DA, Sebisanovic D, Stinson JA, Zhang YR, Seshagiri S, Hillan KJ. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23(25):5900-9, 9/2005. PMID: 16043828.
62. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH, Miller VA. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23(25):5892-9, 9/2005. PMID: 16043829.
63. Liu G, Rugo HS, Wilding G, McShane TM, Evelhoch JL, Ng C, Jackson E, Kelcz F, Yeh BM, Lee FT, Jr, Charnsangavej C, Park JW, Ashton EA, Steinfeldt HM, Pithavala YK, Reich SD, Herbst RS. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 23(24):5464-73, 8/2005. PMID: 16027440.
64. Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 23(24):5474-83, 8/2005. PMID: 16027439.
65. Herbst RS, Arquette M, Shin DM, Dicke K, Vokes EE, Azarnia N, Hong WK, Kies MS. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 23(24):5578-87, 8/2005. PMID: 16009949.
66. Isobe T, Herbst RS, Onn A. Current management of advanced non-small cell lung cancer: targeted therapy. Semin Oncol 32(3):315-28, 6/2005. PMID: 15988686.
67. Onn A, Herbst RS. What is the best way to manage patients treated with gefitinib for non-small-cell lung cancer? Nat Clin Pract Oncol 2(6):290-1, 6/2005. PMID: 16264983.
68. Herbst RS, Onn A, Sandler A. Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 23(14):3243-56, 5/2005. PMID: 15886312.
69. Cella D, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Heyes A, Ochs JS, Wolf MK, Kay AC, Kris MG, Natale RB. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol 23(13):2946-54, 5/2005. e-Pub 2/2005. PMID: 15699477.
70. Gaspar LE, Gay EG, Crawford J, Putnam JB, Herbst RS, Bonner JA. Limited-stage small-cell lung cancer (stages I-III): observations from the National Cancer Data Base. Clin Lung Cancer 6(6):355-60, 5/2005. PMID: 15943896.
71. Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G, Jr, Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao A, Xie D, Ramies DA, Mass R, Seshagiri S, Eberhard DA, Kelley SK, Sandler A. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 23(11):2544-55, 4/2005. PMID: 15753462.
72. Sasaki R, Komaki R, Macapinlac H, Erasmus J, Allen P, Forster K, Putnam JB, Herbst RS, Moran CA, Podoloff DA, Roth JA, Cox JD. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 23(6):1136-43, 2/2005. PMID: 15718309.
73. Herbst RS. Erlotinib. Clin Adv Hematol Oncol 3(2):125, 141, 2/2005. PMID: 16166980.
74. Davis DW, Takamori R, Raut CP, Xiong HQ, Herbst RS, Stadler WM, Heymach JV, Demetri GD, Rashid A, Shen Y, Wen S, Abbruzzese JL, McConkey DJ. Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668. Clin Cancer Res 11(2 Pt 1):678-89, 1/2005. PMID: 15701856.
75. Herbst RS. Current therapeutic strategies in non-small-cell lung cancer: evolving role of docetaxel. Clin Lung Cancer 3:S76, 2005.
76. Zinner RG, Fossella FV, Gladish GW, Glisson BS, Blumenschein GR, Jr., Papadimitrakopoulou VA, Pisters KM, Kim ES, Oh YW, Peeples BO, Ye Z, Curiel RE, Obasaju CK, Hong WK, Herbst RS. Phase II study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. Cancer 104(11):2449-2456, 2005.
77. Herbst RS, Kurzrock R, Parson M, Benjamin R, Chen L, Ng C, Ingram M, Wong S, Chang D, Rosen L. AMG 706 first inhuman, open-label, dose-finding study evaluating the safety and pharmacokinetics in subjects with advanced solid tumors. Eur J Cancer 2(8):48, 2004.
78. Wu W, Shintani T, O'Reilly MS, Herbst RS. Blocking VEGF and EGF receptor signaling with ZD6474 sensitizes human non-small cell lung cancer to chemotherapy with paclitaxel. Eur J Cancer 2(8):50, 2004.
79. Kim E, Mauer A, Fossella F, Kies M, Tran H, Purdom M, Gladish G, Needle M, Vokes E, Herbst R. A phase II study of erbitux (IMC-C225), an epidermal growth factor receptor blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer. Eur J Cancer 38:153, 2002.
80. Tran HT, Herbst RS, Xiong HQ, Madden T, Mulani N, Faria S, Kim K, Charnsangavej C, O'Reilly M, Abbruzzese JL. Phase I trial of recombinant human endostatin administered by continuous infusion intravenously in patients with solid tumors: A preliminary report. Eur J Cancer 38:S73, 2002.
81. Mullani N, Lee K, Herbst R, Tran H, Xiong H, Hess K, O'Reilly M, Charnsangavej C, Abbruzzese J. The effect of human recombinant endostatin on blood flow and glucose metabolism in normal tissues. Eur J Cancer 38:72, 2002.
82. Herbst RS, Arquette M, Nabell L, Kies M, Needle M, Waksal HW, Hong WK. Efficacy and safety of the anti-epidermal growth factor antibody, IMC-C225, in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck refractory to cisplatin containing chemotherapy. Lung Cancer 34:14, 2001.
83. Herbst R, Hess K, Mulliani N, Charnsangavej C, Baker C, Ellis L, Kim EE, Bucana C, Pluda J, Fidler I, Abbruzzese J. A phase I clinical trial of recombinant human endostatin in patients with solid tumors: Surrogate analyses to determine a biologically effective dose. Clin Cancer Res 6:478, 2000.
84. Herbst RS, Khuri FR, Jung M, Fossella FV, Lee JS, Glisson B, Shin DM, Pisters K, Papadimitrakopoulou V, Kurie J, Perez-Soler R, Liu D, Lu C, Zinner R, Guerra M, Munden R, Hong WK. Phase II study of combination weekly gemcitabine and vinorelbine in patients with untreated or previously treated non-small cell lung cancer. Lung Cancer 29(1):12, 2000.
85. Lee JS, Pisters KM, Komaki R, Terry K, Glisson BS, Perez-Soler R, Fossella FV, Shin DM, Herbst RS, Khuri FR, Kurie JM, Hong WK. Systemic chemotherapy as a primary treatment of brain metastasis in patients with non-small cell lung cancer. Lung Cancer 29(1):4, 2000.

Invited Articles
1. William WN, Kim ES, Herbst RS. Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck. Nat Clin Pract Oncol 6(3):132-3, 3/2009. PMID: 19190590.

Editorials
1. Onn A, Herbst RS. Angiogenesis and lung cancer: implications for prognosis and treatment. Lancet Oncol (6)(6):460-1, 6/2007. PMID: 17540301.

Last updated: 10/2/2009